Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials
Clear filter
627 clinical trials found
Clinical trials

MAESTRO-NASH

A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation (NCT03900429)

No longer recruiting

MAGIK

Using implanted markers to determine the feasibility of Markerless Image Guidance using Intrafraction Kilovoltage X-ray Imaging: A Phase I Interventional Study of Lung Cancer Radiotherapy (NCT04086082)

Currently recruiting

MagnetisMM-6

AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA [C1071006] (NCT05623020)

Currently recruiting

Magnitude Study

MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy [ATTR-CM] (NCT06128629)

Currently recruiting

MajesTEC-2

A Multicentre, multi-arm, non-randomised, Phase 1b dose escalation Study of Teclistamab for newly diagnosed or relapsed/refractory MM. (NCT03145181)

No longer recruiting

MajesTEC-4

Phase 3 Study of Teclistamab in Combination with Lenalidomide versus Lenalidomide Alone in Participants with Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4) (NCT05243797)

Currently recruiting

MANTA

Percutaneous Decannulation of Extracorporeal Membrane Oxygenation Using MANTA Vascular Closure Device (ACTRN12621000791831)

No longer recruiting

MARINUS SE [RAISE]

A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of intravenous ganaxolone in status epilepticus (NCT04391569)

Currently recruiting

MARINUS TSC [TRUSTTSC]-DB

A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults with Tuberous Sclerosis Complex (TSC)-related Epilepsy (TrustTSC) (NCT05323734)

Currently recruiting

Maritime CV

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity [MARITIME-CV] (NCT07037433)

The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
Currently recruiting

Maritime HF

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity [MARITIME-HF] (NCT07037459)

This study will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part study with a double-blind period and an open-label extension (OLE). The study is event-driven, and Part 1 will conclude when approximately 850 primary endpoint events have occurred.

Currently recruiting

MarkV-01

A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors (NCT05957081)

Currently recruiting

MASCOT

Interventional, randomized, double-blind, placebo-controlled, optional open-label extension trial of Lu AF82422 in participants with Multiple System Atrophy (NCT06706622)

The purpose of this trial is to find out whether a potential new treatment, the trial drug, Lu AF82422, is safe and effective in people living with Multiple Systems Atrophy (MSA). This trial will compare the effects of the trial drug, Lu AF82422, to placebo (inactive medication). Both the trial drug and placebo will be given as an infusion. Whether progression of MSA will be slowed is measured by a rating scale (questionnaire). The trial will also measure the amount of trial drug in participants blood and cerebrospinal fluid. Participants must have a reliable caregiver who will be available throughout the trial to complete caregiver observer questionnaires when carer/observer-reported outcomes are performed. The trial comprises 2 major periods: a 72-week double-blind PCP and an optional dose-blinded 72 week OLE period.
No longer recruiting

MASTERPLAN

MASTERPLAN: A randomised phase II study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease (NCT04089150)

No longer recruiting

MAT

The Metformin Aneurysm Trial (MAT) (ACTRN12618001707257)

Currently recruiting

MCLA-158-CL03

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma [LiGeR-HN1)

Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Currently recruiting

MEMENTO

MEMENTO - A Phase 4, Single-arm, Open-label Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Assess the Impact on Myocardial Structure with Cardiac Magnetic Resonance Imaging [CMR] (NCT06112743)

No longer recruiting

MHT vs SSRI

A randomised double-blinded interventional trial of estradiol and zoloft to treat menopausal depression (ACTRN12624000475549p)

Currently recruiting

MIDAS 2

A Phase III, Multicentre, Prospective, Randomised, Placebo-controlled, Double-blind, Parallel group, with an adaptive sample size re-estimation study in Stroke Survivors (ACTRN12618000602224)

Currently recruiting

MIST

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation [AP01] in Subjects with Progressive Pulmonary Fibrosis [PPF] (NCT06329401)

Currently recruiting
18 19 20 21 22